Neurocrine Biosciences (NBIX) vs. Its Peers Head-To-Head Analysis
Neurocrine Biosciences (NASDAQ: NBIX) is one of 305 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Neurocrine Biosciences to related companies based on the strength of its risk, analyst recommendations, profitability, earnings, valuation, institutional ownership and dividends.
Institutional and Insider Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.8% of Neurocrine Biosciences shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Neurocrine Biosciences and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Neurocrine Biosciences||$15.00 million||-$141.09 million||-33.10|
|Neurocrine Biosciences Competitors||$290.00 million||$35.57 million||166.06|
Neurocrine Biosciences’ peers have higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Neurocrine Biosciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences’ peers have a beta of 6.54, indicating that their average stock price is 554% more volatile than the S&P 500.
This is a breakdown of current ratings for Neurocrine Biosciences and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Neurocrine Biosciences Competitors||772||3089||11321||227||2.71|
Neurocrine Biosciences currently has a consensus target price of $78.88, indicating a potential upside of 7.34%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.43%. Given Neurocrine Biosciences’ peers higher probable upside, analysts clearly believe Neurocrine Biosciences has less favorable growth aspects than its peers.
This table compares Neurocrine Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Neurocrine Biosciences Competitors||-5,371.93%||-434.15%||-41.51%|
Neurocrine Biosciences peers beat Neurocrine Biosciences on 7 of the 12 factors compared.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.